Biotech News

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.Earnings

Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ( $0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share

Related news

Fulgent Genetics, Inc.

Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and...

Recent company news

Stock data

Close
18.55 USD
Market cap
531.09M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States